Skip to content

The clinical efficacy of Baduanjin in improving metabolic associated fatty liver disease during endocrine therapy after mastectomy

The clinical efficacy of Baduanjin in improving metabolic associated fatty liver disease during endocrine therapy after mastectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000465
Enrollment
Unknown
Registered
2024-09-21
Start date
2024-09-23
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Control group:Aerobic exercise for twelve weeks
Treatment group:Baduanjin practice for twelve weeks

Sponsors

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
50 Years to 69 Years

Inclusion criteria

Inclusion criteria: 1. Female aged50-70 years old in accordance with postmenopausal status: had undergone bilateral oophorectomy; Be aged 60 years or older; Age < 60 years old without drug castration (such as gonadotropin-releasing hormone) and the follicle stimulating hormone estradiol level in postmenopausal range; 2. Non-metastatic estrogen receptor positive and/or progesterone receptor positive early breast cancer confirmed by postoperative pathology stable endocrine therapy for =3 months and the remaining time of treatment =6 months and no other treatment such as radiotherapy or chemotherapy at the present stage; 3. Meet the diagnostic criteria of metabolic-associated fatty liver disease; 4. Abdominal ultrasound or imaging or liver histological examination suggested liver fat accumulation; 5. Meet the diagnostic criteria of qi deficiency and blood stasis syndrome of TCM; 6. Regular exercise <120 minutes per week within 3 months (e.g. continuous brisk walking jogging dancing cycling playing ball etc.); 7. Patients voluntarily participated in this study and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Have a history of acute or chronic viral liver disease autoimmune liver disease alcoholic liver disease hepatolenticular degeneration and other specific liver diseases that can lead to fatty liver; And drugs (ethylamiodarone sodium valproate methotrexate glucocorticoids etc.) total parenteral nutrition inflammatory bowel disease celiac disease hypothyroidism Cushing's syndrome beta-lipoprotein-deficiency lipoatrophic diabetes Mauriac syndrome and other special cases leading to fatty liver; 2. Complicated with ascites or hepatic encephalopathy or liver fibrosis or cirrhosis; 3. Received traditional exercises such as Baduanjin or Yijinjing or Tai Chi in the past 3 months; 4. Patients with unstable weight (weight loss or gain of more than 4kg in the past 3 months); 5. Current use of weight-loss medications (e.g. orlistat) or previous weight-loss (metabolic) surgery; 6. Patients with spinal cord injury spinal cord symptoms severe heart brain and lung diseases etc. unable to participate in the exercise program; 7. Had a stroke or myocardial infarction in the past year; 8. Patients with dementia bipolar disorder and other major mental diseases language disorders or other reasons can not cooperate with the study or refuse to take blood; 9. Being ready for pregnancy or pregnant or lactating (ruled out by urinary HCG); 10. Current smokers; 11. Combined with any other malignant tumors; 12.Patients with distant metastasis of breast cancer especially bone metastasis; 13. Allergy to the study drug or its excipients; 14. Who participated in other clinical trials during the same period or within the previous 3 months.

Design outcomes

Primary

MeasureTime frame
magnetic resonance imaging proton density fat fraction;

Secondary

MeasureTime frame
Liver function;Plasma high-sensitivity C-reactive protein levels;glycosylated hemoglobin;blood lipid;Homeostasis model evaluation - Insulin resistance index;Multidimensional Fatigue Symptom scale-Short form;body composition;inflammatory cytokines;attendance rate;fasting blood-glucose;

Countries

China

Contacts

Public ContactSheng Jiayu

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of Traditional Chinese Medicine

sjy1983@126.com13361990930

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026